KR910016333A - 피록시캄/사이클로덱스트린 복합체의 제조방법, 이로인해 수득된 생성물 및 이의 약제학적 조성물 - Google Patents

피록시캄/사이클로덱스트린 복합체의 제조방법, 이로인해 수득된 생성물 및 이의 약제학적 조성물 Download PDF

Info

Publication number
KR910016333A
KR910016333A KR1019910004755A KR910004755A KR910016333A KR 910016333 A KR910016333 A KR 910016333A KR 1019910004755 A KR1019910004755 A KR 1019910004755A KR 910004755 A KR910004755 A KR 910004755A KR 910016333 A KR910016333 A KR 910016333A
Authority
KR
South Korea
Prior art keywords
complex
cyclodextrin
pyroxicam
pharmaceutical composition
composition
Prior art date
Application number
KR1019910004755A
Other languages
English (en)
Other versions
KR0175934B1 (ko
Inventor
카를리 파비오
치에시 파올로
Original Assignee
치에시 파올로
치에시 파마슈티시 에스.피.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치에시 파올로, 치에시 파마슈티시 에스.피.에이. filed Critical 치에시 파올로
Publication of KR910016333A publication Critical patent/KR910016333A/ko
Application granted granted Critical
Publication of KR0175934B1 publication Critical patent/KR0175934B1/ko

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

내용 없음

Description

피록시캄/사이클로덱스트린 복합체의 제조방법, 이로인해 수득된 생성물 및 이의 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. a)분말형의 피록시캄 및 사이클로덱스트린을 고체상태로 함께 혼합하고, 임의로 탈기시키며; b)수득한 혼합물을 증기로 포화된 분쇄실이 있는 고에너지 분쇄기에서 공-분쇄시키고; c)수득한 생성물을 진공하에서 건조시킨 후, 체질(screening)하여 용집체를 제거함을 특징으로 하여, 피록시캄-사이클로덱스트린 복합체를 제조하는 방법.
  2. 제 1 항에 있어서, 사이클로덱스트린 대 피록시캄의 중량비가 10 : 1 내지 1 : 1임을 특징으로 하는 방법.
  3. 제 1 항에 있어서, 공-분쇄를 0.10 내지 48시간동안 수행함을 특징으로 하는 방법.
  4. 제 1 항에 있어서, 공-분쇄를 0.25 내지 4시간동안 수행함을 특징으로 하는 방법.
  5. 평형 용해도가 60 내지 100mg/ℓ이고 과포화치(Cmax)가 100내지 1000mg/ℓ이며, 수-접촉각이 55°이하임을 특징으로 하는, 제1 내지 4항중 한 항의 방법에 따라 수득된 피록시캄/사이클로덱스트린 복합체.
  6. 활성 성분으로 제5항의 복합체를 함유하는, 진통, 소염 및 항류마티스성 활성을 지닌 경구, 직장 및 국소 투여용 약제학적 조성물.
  7. 제6항에 있어서, 단위 용량당 상기 복합체 10 내지 50mg을 함유하는 경구 또는 직장 투여용 조성물.
  8. 제6항에 있어서, 상기 복합체 0.2 내지 5중량%를 함유하는 국소 투여용 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910004755A 1990-03-27 1991-03-27 피록시캄/사이클로덱스트린 복합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 KR0175934B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT19829A IT1241088B (it) 1990-03-27 1990-03-27 Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
IT19829/90 1990-03-27

Publications (2)

Publication Number Publication Date
KR910016333A true KR910016333A (ko) 1991-11-05
KR0175934B1 KR0175934B1 (ko) 1999-03-20

Family

ID=11161628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910004755A KR0175934B1 (ko) 1990-03-27 1991-03-27 피록시캄/사이클로덱스트린 복합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (24)

Country Link
US (1) US5164380A (ko)
EP (1) EP0449167B1 (ko)
JP (1) JPH04221314A (ko)
KR (1) KR0175934B1 (ko)
AT (1) ATE157883T1 (ko)
AU (1) AU644417B2 (ko)
CA (1) CA2039052C (ko)
CZ (1) CZ280164B6 (ko)
DE (1) DE69127566T2 (ko)
DK (1) DK0449167T3 (ko)
ES (1) ES2107430T3 (ko)
FI (1) FI102461B (ko)
GR (1) GR3025305T3 (ko)
HU (1) HU217834B (ko)
IE (1) IE910969A1 (ko)
IL (1) IL97693A (ko)
IT (1) IT1241088B (ko)
MA (1) MA22089A1 (ko)
NO (1) NO178456C (ko)
NZ (1) NZ237583A (ko)
PT (1) PT97176B (ko)
RU (1) RU2034544C1 (ko)
SK (1) SK279171B6 (ko)
ZA (1) ZA912282B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254541A (en) * 1991-11-15 1993-10-19 Merck Frosst Canada, Inc. (Quinolin-2-ylmethoxy)indole/cyclodextrin complex
IL111184A (en) * 1993-10-08 2000-08-13 Farmarc Nederland B V Of Cito Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7255877B2 (en) 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
IT1295289B1 (it) * 1997-10-07 1999-05-04 Telos S R L Co-macinati per uso cosmetico e dermatologico
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
SK288117B6 (sk) * 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
US20060073188A1 (en) * 1999-03-31 2006-04-06 Pierre Fabre Medicament Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
FR2868315B1 (fr) * 2004-04-01 2006-07-14 Pierre Fabre Medicament Sa Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
EP1729813B1 (fr) 2004-04-01 2011-04-06 Pierre Fabre Medicament Complexes d'inclusions comprenant du piroxicam, une cyclodextrine et l'arginine
US8715731B2 (en) * 2006-03-22 2014-05-06 Isp Investments Inc. Process of reducing the bitter taste of water soluble actives by co-grinding the active with β cyclodextrin
JP5552400B2 (ja) * 2010-09-07 2014-07-16 東亜薬品株式会社 生薬類の苦味・不快味をマスキングした顆粒剤、及び口腔内速崩壊錠
CN102008450B (zh) * 2010-12-10 2013-01-30 杭州艾瑞莎生物医药科技有限公司 一种药物-环糊精纳米颗粒及其制备方法
ITMI20120092A1 (it) 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
ITUB20161027A1 (it) * 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
KR102337124B1 (ko) * 2021-05-13 2021-12-10 (주)바이오제닉스 탈모 개선용 복합 파우더 및 이를 포함하는 모발용 화장료 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS6165805A (ja) * 1984-09-10 1986-04-04 Nippon Ekishiyou Kk 防殺虫フイルムの製造方法
US4579846A (en) * 1984-10-11 1986-04-01 Pfizer Inc. Antiinflammatory compositions and methods
US4672061A (en) * 1985-01-28 1987-06-09 Pfizer Inc. Antiinflammatory compositions and methods
IT1196307B (it) * 1984-10-22 1988-11-16 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam monoidrato
US4888343A (en) * 1986-09-15 1989-12-19 Bristol-Myers Company Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process
US5081118A (en) * 1987-10-26 1992-01-14 Pfizer Inc. Benzothiazine dioxide derivatives
US5068226A (en) * 1987-12-07 1991-11-26 Cyclex, Inc. Pharmaceutical preparations containing cyclodextrins and their use in iontophoretic therapies
IT1216686B (it) * 1988-04-01 1990-03-08 Chiesi Farma Spa Formulazioni farmaceutiche acquose di piroxicam e procedimento per laloro preparazione.
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione

Also Published As

Publication number Publication date
RU2034544C1 (ru) 1995-05-10
AU7383891A (en) 1991-10-03
HUT60738A (en) 1992-10-28
ATE157883T1 (de) 1997-09-15
IT9019829A1 (it) 1991-09-27
FI911448A0 (fi) 1991-03-26
ZA912282B (en) 1991-12-24
IE910969A1 (en) 1991-10-09
KR0175934B1 (ko) 1999-03-20
IT1241088B (it) 1993-12-29
NO911216D0 (no) 1991-03-25
EP0449167B1 (en) 1997-09-10
IL97693A0 (en) 1992-06-21
FI911448A (fi) 1991-09-28
NO178456B (no) 1995-12-27
IL97693A (en) 1995-03-30
PT97176A (pt) 1991-11-29
CS9100833A2 (en) 1991-10-15
CA2039052C (en) 2002-07-30
GR3025305T3 (en) 1998-02-27
PT97176B (pt) 1998-07-31
SK279171B6 (sk) 1998-07-08
CZ280164B6 (cs) 1995-11-15
IT9019829A0 (it) 1990-03-27
EP0449167A1 (en) 1991-10-02
DE69127566T2 (de) 1998-02-12
FI102461B1 (fi) 1998-12-15
US5164380A (en) 1992-11-17
NO911216L (no) 1991-09-30
DK0449167T3 (da) 1998-03-09
AU644417B2 (en) 1993-12-09
NO178456C (no) 1996-04-03
HU911016D0 (en) 1991-10-28
JPH04221314A (ja) 1992-08-11
NZ237583A (en) 1992-08-26
MA22089A1 (fr) 1991-10-01
DE69127566D1 (de) 1997-10-16
HU217834B (hu) 2000-04-28
FI102461B (fi) 1998-12-15
ES2107430T3 (es) 1997-12-01
CA2039052A1 (en) 1991-09-28

Similar Documents

Publication Publication Date Title
KR910016333A (ko) 피록시캄/사이클로덱스트린 복합체의 제조방법, 이로인해 수득된 생성물 및 이의 약제학적 조성물
DE2822882C2 (ko)
KR850000975A (ko) 발프로익산과 그 염의 혼합물을 토대로 한 조성물
ES2160577T3 (es) Nuevos esteres de aminoalcoholes biciclicos y triciclicos, su preparacion y su utilizacion en medicamentos.
IE782019L (en) Pharmaceutical compositions
IL42232A (en) Dry medicines for oral administration
CA2209167A1 (en) Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereof
KR880004803A (ko) 분무 건조된 아세트아미노펜
JPS5671046A (en) Aqueous solution of nitroglycerin and its preparation
ATE38834T1 (de) 5-substituierte 1,2,4-oxadiazol-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
HU9400430D0 (en) New pyrazine derivatives, their preparation and pharmaceutical compositions containing them
ES2029254T3 (es) Procedimiento para la preparacion de una sal de diclofenac con una base organica ciclica.
JPS605580B2 (ja) 新ナフタレン誘導体の製法
KR910011241A (ko) 정제로 직접 압착 가능한 약제학적 분말 조성물을 제조하기 위한 분무 건조법
JPS5420126A (en) Pharmaceutical composition
ES370058A1 (es) Procedimiento para la preparacion de composiciones farma- ceuticas efervescentes.
JPS5781409A (en) External plaster
IE32453L (en) Pteridine derivatives
US2906665A (en) L-amphetamine alginate
JPS57126414A (en) Ointment
BE884716A (fr) Derives du 1,1,2-triphenylpropane et du 1,1,2-triphenylpropene procede de preparation de ces derives et compositions pharmaceutiques contenant ces nouveaux composes
JPS5283428A (en) Preparation of aromatic carboxylic acid amide derivatives
US3242049A (en) Process for making enterically useful complex of spiramycin and product thereof
KR890001559A (ko) 트라피딜을 함유하는 제약 조성물, 그의 제조방법 및 관련된 치료 용도
JPS5721319A (en) Agent for improving desorder of circulatory orgen

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20091113

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee